SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Elon Musks warning that neocloud providers face failures and consolidation has intensified selling in CoreWeave and renewed concern about its debt-heavy, capital-intensive AI infrastructure model and access to financing. Traders debate whether Musk is criticizing a competitor for self-interest, while bulls point to AI demand and Nvidias backing and bears focus on borrowing costs, dilution, and execution risks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure alongside AI data-center and neocloud stocks as traders debate financing risks and Elon Musks warning that tighter credit could trigger failures among smaller operators. Bears fear debt, dilution and execution challenges, while bulls argue IRENs contracts, power access and AI partnerships distinguish it and point to continued compute demand.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp neocloud selloff tied to Elon Musks warning of tighter financing and consolidation among AI infrastructure providers, intensifying concerns about debt-funded expansion and data-center returns. Traders disagree on whether Nebius is vulnerable to sector-wide risks or better positioned because of its financing access and demand for AI compute.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Merck are driving discussion: traders broadly view the data as clinically promising, but the shares sold off as investors judged them against high expectations after a sharp rally. Bulls see validation for a broader cancer-vaccine platform, while bears question its commercial potential, costs and valuation.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazilian equities sold off sharply after Lulas election victory, as traders voiced concerns about policy and economic uncertainty; some alleged election irregularities without evidence. Others called the move an overreaction and viewed the drop as a buying opportunity.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs REGAL Phase 3 trial of GPS for AML, with traders watching for the 80th survival event that would trigger final analysis and eventual topline results. The prolonged wait and company silence fuel debate: bulls speculate that slower event accrual reflects longer survival and possible ASH-related disclosure, while skeptics warn that the delay is uncertain and could signal problems; SLS009 data is a secondary focus.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is drawing attention amid volatile, headline-driven trading around uncertainty over possible U.S.-Iran action and oil prices; traders are split between expecting a relief bounce on no-strike signals and warning that unresolved tensions could sustain inflation and market risks. The Fed decision and major technology earnings are also adding to expectations for choppy trading.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is caught in a broad selloff in AI data-center and neocloud stocks, as traders debate debt, financing costs, and whether the sectors expansion can generate returns. Some see the decline as a buying opportunity, pointing to insider purchases and contracted growth; speculation about future hyperscaler deals and enthusiasm around AI spending compete with concerns about execution and dilution.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Lulas election victory is prompting debate over political risk and its implications for Petrobras, with some traders concerned about government influence and others arguing that strong oil economics could cushion the stock. The community is split between selling on election uncertainty and viewing the selloff as panic.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Nu Holdings strong quarterly results, including record profitability and continued growth, are driving bullish attention, with traders praising the business momentum. Some remain cautious about credit quality and the stocks volatile price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BrainStorm Cell Therapeutics Crashes After Hours On Nasdaq Delisting Notice; Retail Sees 'Buy Time'

Equity

The company plans to move its shares to the OTCQB market and says the delisting won't impact its ALS research or upcoming Phase 3b trial. 

Retail Bulls Cheer FDA Clearance For BrainStorm’s ALS Therapy, But Shares Dip After Hours

BrainStorm Cell Therapeutics plans to enroll 200 ALS patients in its FDA-cleared Phase 3b trial of NurOwn, with a 24-week double-blind phase followed by an open-label extension.

News Movers: Yesterday’s Hottest News That Could Move the Needle Today

Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks

Brainstorm Cell Therapeutics Inc. reported a net loss of $3.855 million for the three months ended June 30, 2026, compared to a net loss of $2.903 million in the prior year.

Brainstorm Cell Therapeutics Inc. faces significant financial risks, including substantial doubts regarding its ability to continue as a going concern, material internal control weaknesses, and ongoing litigation with a medical center.

Brainstorm Cell Therapeutics Inc. has achieved critical regulatory milestones for its NurOwn Phase 3b ALS trial, supported by a strong intellectual property portfolio and ongoing strategic manufacturing developments.

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Brainstorm Cell Therapeutics, Inc.

Bearish Sentiment

Shares of BrainStorm Cell Therapeutics slipped in after-hours trading Thursday after the company said&nbsp;it has been removed from the Nasdaq Capital Market for falling short of minimum equity requirements.The stock will stop trading on Nasdaq when&nbsp;the&nbsp;markets open Friday.&nbsp;Brainstorm Cell’s stock plunged 42.7% in after-hours trading on Thursday, falling to $0.67, following a 2.5% dip during the regular session.The company said it has received approval to shift its listing to the OTCQB Venture Market, where it will continue trading under the same ticker.“While this delisting is a difficult outcome, it does not change our core mission or our dedication to the ALS community,” said CEO Chaim Lebovits. “Our move to the OTCQB ensures trading continuity and allows us to maintain focus on advancing NurOwn.”NurOwn is BrainStorm’s experimental cell therapy for ALS, a progressive disease that steadily weakens muscles and shortens lives.&nbsp;The company is preparing to launch a pivotal Phase 3b trial, designed in coordination with the FDA under a Special Protocol Assessment agreement.In June, BrainStorm released new survival data from 10 ALS patients who received NurOwn through its Expanded Access Program.The company reported that 90% of those patients survived more than five years from symptom onset, marking a significant contrast to the roughly 10% survival rate reported in the general ALS population.&nbsp;The median survival was 6.8 years, with the only death attributed to elective euthanasia.To support the upcoming trial, BrainStorm recently entered a manufacturing agreement with Minaris Advanced Therapies, a U.S.-based contract development and manufacturing organization.&nbsp;It has also partnered with Israel-based Pluri to expand clinical supply capabilities.The company stated that the Nasdaq delisting will not affect its business operations, R&amp;D activities, or its commitment to shareholders.On Stocktwits, retail sentiment for Brainstorm was ‘bullish’ amid ‘high’ message volume.One user said that BrainStorm can possibly tap the at-the-market (ATM) facility to fund its upcoming trial, citing the stock’s rebound.<stembedurl>https://stocktwits.com/steven_glandsberg/message/621369650</stembedurl>Another user saw the dip as a buying opportunity, calling it a “good buy time.”<stembedurl>https://stocktwits.com/bigdave100/message/621361783</stembedurl><a href="https://stocktwits.com/symbol/BCLI">Brainstorm’s stock</a> has declined 45.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a man walking in front of the Nasdaq building at Times Square in New York. (Photo by John Smith/VIEWpress)

Shares of BrainStorm Cell Therapeutics slipped in after-hours trading Thursday after the company said it has been removed from the Nasdaq Capital Market for falling short of minimum equity requirements.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$0.8219
Prev Close	$0.776
Open	$0.7999
Dividend Yield	0.00%
50-Day Moving Average	$0.9822
Beta	0.15
Avg. Volume	14,096.38
PE Ratio	-0.86

52-Week High	$1.69
52-Week Low	$0.4589
Market Capitalization	$9.07M
EPS (Annual)	-$1.11
Price to Book	-0.78
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCLI Fundamentals